Biotech Rockets 170% on Clinical Breakthrough 🚀

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. 

I’m back from brief hiatus with a fresh helping of hot stocks. I appreciate your patience with us the past couple of days!

Here’s what moved the market today.

Markets 📈

U.S. stocks continued to march higher in the wake of last week’s Fed meeting. Even the small-cap Russell 2K returned to form after pulling back on Friday.

Sponsored

A Cancer Stock with MASSIVE Potential

A revolutionary shift in medical innovation and could skyrocket this overlooked biotech stock.

It could deliver the next-generation of cancer treatments and drive massive windfalls for shareholders.

ADD THIS STOCK TO YOUR WATCHLIST!

Market-Moving News 🔎 

⚖ Federal Judge Dismisses Tylenol Autism, ADHD Lawsuits

In a significant decision, U.S. District Judge Denise Cote in Manhattan ruled against over 400 consolidated lawsuits targeting Tylenol and generic acetaminophen manufacturers.

The plaintiffs claimed that using the pain reliever during pregnancy increased the risk of autism or ADHD in children, but the judge found their scientific evidence unreliable.

💼 Case Details:
Judge Cote criticized the plaintiffs' scientific approach as “unstructured,” prone to selective data use, and failing to address the complexities and inconsistencies in their data.

The defendant manufacturers, including Kenvue [KVUE +2.0%], argued that autism and ADHD are genetic disorders, with no conclusive evidence linking them to in-utero exposure to acetaminophen.

🔬 Acetaminophen's Safety Profile: 
Acetaminophen has been widely regarded as the safest pain relief option during pregnancy. Its label advises pregnant women to consult their doctor before use.

Kenvue and other drugmakers maintain that acetaminophen is one of the most studied medications and is recommended by doctors for pain and fever relief during pregnancy.

📝 Next Steps: 
Kenvue announced plans to request the dismissal of these lawsuits, emphasizing the need to clarify acetaminophen's safety record.

This court decision marks a pivotal moment in the ongoing debate over the safety of widely used medications during pregnancy, with significant implications for both consumers and pharmaceutical companies.

Compugen [CGEN] $2.00 (+173.9%)
said a AstraZenece [AZN 0.0%] clinical trial will trigger a $10 million milestone payment to Compugen upon dosing of the first patient.

ProSomnus [OSA] $0.9907 (+57.6%)
published new clinical data demonstrating the successful treatment of obstructive sleep apnea with its ProSomnus Precision oral devices.

Panbela Therapeutics [PBLA] $1.57 (+55.4%)
could receive up to $9.5 million milestone payments after the FDA approved US WorldMeds’s eflornithine for neuroblastoma.

Motus GI [MOTS] $1.31 (39.0%)
announced a $5.0 million public offering of 3.3 million shares of its common stock, plus accompanying warrants.

Cuentas [CUEN] $1.01 (54.3%)
received a Nasdaq notice informing it that its stock will be suspended from the exchange on Dec. 20th. Cuentas plans to appeal the decision.

GSE Systems [GSE] $2.04 (36.0%) 
filed an SEC disclosure for the resale of up to 1.73 million shares of common stock from certain selling shareholders.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback from our members!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Text ELITESTOCKS to 47121 or click here to get our alerts on your mobile device, and never miss another fast-moving stock!

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.